MedActive Oral Pharmaceuticals has launched a protocol trial using patients with Sjögren's syndrome to test its products for relief of xerostomia.
Xerostomia is caused by salivary gland dysfunction, one of the symptoms associated with Sjögren's syndrome, the company noted in a press release.
MedActive makes oral care products that address the need for continuous and comprehensive management of salivary dysfunction, mucosal hydration, bacterial overgrowth, sensitivity, oral thrush, inflammation, demineralization, and loss of taste caused by chronic illnesses, commonly prescribed medications, various therapies, occupational hazards, and lifestyle.
The company invited 3,000 members of the Sjögren's Syndrome Foundation to participate in the month-long evaluation of MedActive oral relief lozenges, spray, and gel, which are formulated to provide relief for corrupted oral cavities that typically manifest high sensitivity to anything taken orally.
Medical and dental professionals report a huge increase in the number of patients with chronic illnesses manifesting adverse oral side effects, such as dry mouth, oral thrush, increased cavities, and burning mouth, which can negatively impact health and quality of life, the company noted.
